Scientists at MIT and other institutions engineered parasitic roundworms to manufacture and deliver drugs directly inside a living body, opening a potential new pathway for treating diseases. The research team, led by investigators at the Broad Institute, modified Caenorhabditis elegans, a common intestinal nematode, to produce therapeutic proteins that the worm then released into the host's bloodstream.
The proof-of-concept experiment worked in laboratory conditions. Researchers inserted genes encoding insulin and other therapeutic proteins into the worms' cells. Once inside a host organism, the modified worms produced these proteins continuously and released them into circulation where they could treat disease. The approach bypassed traditional drug delivery challenges like protein degradation and immune rejection.
The worms colonize the intestines naturally, providing a persistent bioreactor within the body. Unlike injected medications that require repeated doses, this living delivery system could theoretically maintain therapeutic levels continuously. The team demonstrated protein production lasted weeks in their experimental setup.
The work appears conceptually sound but faces significant hurdles before clinical use. Safety remains the primary concern. Parasitic worms cause serious infections, and releasing engineered organisms into human patients raises infection control questions. Researchers must ensure the modified worms cannot spread between people and that host immune responses don't eliminate them prematurely. Dosage control also presents challenges; stopping drug production requires eliminating the worms themselves.
The team published findings showing proof-of-concept in controlled laboratory settings, but human trials remain distant. Regulatory pathways for genetically modified living therapeutics remain unclear. The approach works best for proteins the stomach acid would normally destroy, making it potentially valuable for treating diabetes, hormone deficiencies, and immune disorders.
Other research groups have explored engineered bacteria and viruses as living drug factories, but using parasitic worms offers advantages. The worms' larger size and complexity allow more sophisticated genetic modifications